7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

BioVie Inc
(NASDAQ:BIVI) 

BIVI stock logo

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly...

Founded: 2013
Full Time Employees: 2
CEO: Terren S. Peizer  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
BioVie Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.18-1.01-0.84-0.67-0.5-0.34-0.170
BioVie Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.18-1.01-0.84-0.67-0.5-0.34-0.170
BioVie Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.210.420.630.841.051.261.47
BioVie (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -8.28-7.09-5.91-4.73-3.55-2.36-1.180
BioVie P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 05.0710.1315.220.2725.3430.435.47
No extra charts and metrics for this ticker.